Welcome to our dedicated page for Solid Bioscience SEC filings (Ticker: SLDB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Solid Biosciences Inc. (SLDB) files reports and disclosures with the U.S. Securities and Exchange Commission as a Nasdaq-listed issuer. These SEC filings provide detailed information on the company’s clinical programs, financial condition, risk factors and material corporate events related to its development of precision genetic medicines for rare neuromuscular and cardiac diseases.
Among the documents available, Form 10-K annual reports and Form 10-Q quarterly reports typically discuss Solid Biosciences’ gene therapy pipeline, including SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia and SGT-601 for TNNT2-mediated dilated cardiomyopathy, along with its AAV-SLB101 capsid platform and broader development activities. These filings outline the company’s business description, research and development focus and key risks.
Form 8-K current reports, such as the filing describing interim data from the INSPIRE DUCHENNE Phase 1/2 trial of SGT-003, provide updates on material events, including clinical data readouts, regulatory developments, corporate presentations and other significant announcements. Investors can also review information on equity awards and stock plans, as referenced in company communications about inducement grants made under Nasdaq Listing Rule 5635(c)(4).
This SEC filings page offers real-time access to Solid Biosciences’ submissions from the EDGAR system, along with AI-powered summaries that highlight key points from lengthy documents. Users can quickly identify disclosures on clinical trial progress, gene therapy strategy, regulatory interactions and other factors that may be important when evaluating SLDB.
Solid Biosciences Chief Operating Officer sells shares to cover taxes. On February 4, 2026, COO David T. Howton sold 18,894 shares of Solid Biosciences common stock at a weighted average price of $6.4419 per share.
The filing explains this was an automatic sale to cover withholding taxes after restricted stock units vested, under a pre-established durable automatic sale instruction. It states the transaction was not a discretionary trade. After this sale, Howton directly owned 97,859 shares of common stock.
Solid Biosciences Inc. President and CEO Alexander Cumbo reported an automatic sale of common stock tied to tax withholding. On February 4, 2026, he sold 48,913 shares of Solid Biosciences common stock at a weighted average price of $6.4419 per share.
The filing explains this was a sell-to-cover transaction to satisfy withholding taxes after previously granted restricted stock units vested, executed under a durable automatic sale instruction letter adopted on August 18, 2024. After this activity, Cumbo directly beneficially owned 222,018 common shares.
Solid Biosciences Inc. director Ilan Ganot reported an indirect sale of 7,205 shares of common stock on February 4, 2026 at a weighted average price of $6.4419 per share. The shares were held through his spouse and sold to cover withholding taxes after previously granted restricted stock units vested, under a durable automatic sell-to-cover instruction, so the transaction was not a discretionary trade.
Following this transaction, Ganot is reported as beneficially owning 25,271 shares indirectly through his wife, 99,297 shares directly (including shares held individually and jointly with Annie Ganot), and 19,394 shares indirectly through the Ilan Ganot 2017 Irrevocable Trust.
Solid Biosciences Inc. CFO and Treasurer Kevin Tan reported an automatic sale of 14,783 shares of common stock on February 4, 2026. The shares were sold at a weighted average price of $6.4419 per share, in multiple trades between $6.28 and $6.60.
The sale was made solely to cover withholding taxes after previously granted restricted stock units vested, under a durable automatic sale instruction letter adopted on August 15, 2024, and is not a discretionary trade by Mr. Tan. Following this transaction, he directly holds 94,201 common shares.
Solid Biosciences Inc. Chief Medical Officer Gabriel Brooks reported an automatic sale of 12,616 shares of common stock on February 4, 2026. The shares were sold at a weighted average price of
After this tax-withholding sale, Dr. Brooks beneficially owns 84,092 shares of Solid Biosciences common stock in direct form. The company’s disclosure notes that the transaction did not represent a discretionary trade by Dr. Brooks, and that the individual sale prices ranged from
Solid Biosciences Inc. insider transaction: Chief Regulatory Officer Jessie Hanrahan reported an automatic sale of common stock tied to tax withholding. On February 4, 2026, 12,348 shares of common stock were sold at a weighted average price of
Solid Biosciences Inc. Chief Technology Officer Paul Herzich reported a small, routine share sale on a Form 4. On February 4, 2026, he sold 10,905 shares of common stock at a weighted average price of $6.4419 per share.
According to the filing, the sale was made solely to cover withholding taxes after previously granted restricted stock units vested, under a pre-established durable automatic sale instruction. It was not a discretionary trade. After this transaction, Herzich beneficially owned 69,067 shares directly.
Solid Biosciences insider files notice to sell shares. A person named Kevin Tan filed to sell 14,783 shares of Solid Biosciences common stock through E*TRADE, with an aggregate market value of $95,226.63, on or about 02/04/2026 on NASDAQ, with 82,569,192 shares outstanding.
The 14,783 shares come from vested restricted stock units that settled on 02/04/2026 as compensation from the issuer. Over the prior three months, Kevin Tan sold 5,704 shares for $30,060.08 on 01/13/2026 and 26,837 shares for $172,747.09 on 02/02/2026.
Solid Biosciences insider Paul Herzich has filed a notice under Rule 144 to sell 10,905 shares of the company’s common stock through E*TRADE on or about 02/04/2026, to be traded on NASDAQ. The aggregate market value of the planned sale is 70,246.73.
The shares to be sold were acquired the same day through settlement of vested restricted stock units as compensation from the issuer. The filing also reports that, over the past three months, Herzich sold 2,701 shares for gross proceeds of 13,802.11 and 26,250 shares for gross proceeds of 168,968.63.
Solid Biosciences insider Ilan Ganot has filed a Form 144 to sell common stock. The notice covers an intended sale of 7,205 shares of Solid Biosciences common stock through E*TRADE Financial Corporation on or about February 4, 2026, with an aggregate market value of $46,411.95. These shares were acquired the same day via settlement of vested restricted stock units, held indirectly through his wife, as compensation from the issuer. Over the prior three months, Ganot reported additional sales of 3,278, 1,053 and 191 shares of common stock, generating gross proceeds of $13,505.36, $5,717.79 and $1,258.69, respectively.
FAQ
What is the current stock price of Solid Bioscience (SLDB)?
What is the market cap of Solid Bioscience (SLDB)?
